Out today! Stewardship prompts to improve antibiotic selection for pneumonia & UTI - 2 INSPIRE RCTs - Reduced empiric extended-spectrum antibiotic use by 28.4% and 17.4% in hospitalized patients with pneumonia & UTI, respectively. jamanetwork.com/journals/jama/… jamanetwork.com/journals/jama/…

🔼🔥Prospective, multicenter, non-inferiority, randomized study Clinical Microbiology and Infection 7 hospitals in 🇨🇱 Efficacy and safety of withholding antimicrobial therapy in children with cancer,fever and neutropenia,with a demonstrated viral respiratory infection #IDXposts clinicalmicrobiologyandinfection.com/article/S1198-…

Preparing your schedule for #ESCMIDGlobal ? Make sure you attend the late-breaking clinical trials in AMR, Monday April 29 8:30-9:30am in Hall E. Along with trials from Brett Mitchell and Antibacterial Resistance Leadership Group the team that brought you the MERINO trial will be there...

📌WHO is reviewing the antifungal clinical and preclinical pipeline and is inviting developers to share information on their preclinical research projects. Closing date: 22.05.2024 Link: lnkd.in/dQWMUQPY FPPL : lnkd.in/dcQtea2g World Health Organization (WHO) #R&D #Antifungal

Today we approved new tablets to treat female adults with uncomplicated urinary tract infections (UTIs) caused by susceptible isolates of Escherichia coli, Proteus mirabilis and Staphylococcus saprophyticus. fda.gov/news-events/pr… Uncomplicated UTIs are bacterial infections of

Rapid diagnostic tests and antimicrobial stewardship programs: What is their relative contribution to improving clinical outcomes in BSI? Great work by Anna Maria Peri Patrick Harris academic.oup.com/cid/article/do…

📣 PUBLISHED TODAY: CARB-X’s 2023 Annual Report is out! The report highlights key takeaways from the portfolio strategy review, funding round results, our work in low- and middle-income countries, new CARB-X funders, & more: bit.ly/49YZjOx

We have enrolled the first patient in the pivotal Phase 3 study of VE303 for the prevention of recurrent C. difficile Infection. To our knowledge, this is the 1st registrational study of a Live Biotherapeutic Product for rCDI An important milestone in our field /1

🆕️🔥Cohort study that has the largest international registry-based meta-analysis performed to date JAMA Network Open The risk of revision for PJI was similar between antibiotic-loaded bone cement and plain bone cement following primary TKA #idxposts jamanetwork.com/journals/jaman…

🍄 Antifungal Drug Developers this is for you! 🐀 If you are in the preclinical stage: please fill our survey! The deadline has been extended until 17 June 2024! 👇 Link below. Richard Alm

Please share: 🚀 Our startup accelerator program is now accepting applications from early-stage companies! 🧬 We work with awesome teams that digitally enable life science! 📈 We provide funding, space, mentoring, and more! See website for details: mds.studio

The Fujimori Lab UCSF is looking for a junior specialist (research technician). Great opportunity to obtain two years of research experience UC San Francisco in a supportive, interdisciplinary environment before grad school! Please RT - thanks! aprecruit.ucsf.edu/JPF05091

SEP-1 links CMS reimbursement to hospitals with broad spectrum antibiotic administration < 3 hrs from possible sign of sepsis, driving harmful mis-use of abx. Looking forward to a new sepsis mortality quality measure in the CMS value-based program, rewarding diagnostic use

Very pleased to see our latest article published in ESCMID Clinical Microbiology and Infection With @JenniferCohn2 Brenda Waning Mirfin Mpundu DrPH Hema Srinivasan Yewande Alimi MD clinicalmicrobiologyandinfection.com/article/S1198-…

After months of hard work and collaboration, Congresswoman Yvette D. Clarke introduced the Peggy Lillis Clostridioides difficile Inclusion Act. Thank you Congresswoman Clarke for your work on this. Show your support for the bill here buff.ly/3WAi2fR

ePhective (San Francisco) is a newly founded #phagetherapy company started by Joe Bondy-Denomy (UC San Francisco) & Zemer Gitai (Princeton University). They are currently looking for: 2 #Phage Scientists to lead projects in phage discovery, characterization, & engineering

ePhective Therapeutics is looking for phage scientists to join us in the South San Francisco area for an exciting new endeavor!

Looking forward to discussing market access strategy with medical device developers at #MTC24 over the next few days alongside the Rubrum Advising leadership team. #medtechcon

To my biotech friends, come take a peek behind the curtains of medtech! In this piece, we focus on the innovations that have been brought to market through the Breakthrough Device Designation program. Great insights from my boss and the former CMO of CMS, Lee Fleisher.

This is a topic I look forward to addressing as a co-presenter of Workshop B at the Bacteriophage Therapy Summit tomorrow. #phage